CG
AQST icon

Cutler Group’s Aquestive Therapeutics AQST Stock Holding History

Cutler Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,100
Closed -$3K – 4764
2020
Q3 		$3K Buy
5,100
+4,100
+410% +$26.8K ﹤0.01% 3773
2020
Q2 		$1K Buy
+1,000
New +$4.6K ﹤0.01% 3940

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cutler Group's AQST Position: Q4 2021 in Review

Cutler Group sold out of Aquestive Therapeutics (AQST) in Q4 2021, closing a stake of 300 shares — an estimated $1K sold.

Cutler Group first reported a position in AQST in Q4 2020 and held it in 4 quarters. The position peaked at $16K in Q4 2020. 52 funds tracked by Wall St. Rank hold AQST as of Q4 2021.

  • Cutler Group reported no remaining Aquestive Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 300 Aquestive Therapeutics shares in Q4 2021, an estimated $1K.
  • Cutler Group first reported a position in Aquestive Therapeutics in Q4 2020 and held it in 4 quarters.
  • Cutler Group's Aquestive Therapeutics position peaked at $16K in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.